Schifferstadt, Germany

Reinhold Müller

This inventor holds 2 USPTO granted patents. Top assignees: Abbott Gmbh & Co Kg, Basf Aktiengesellschaft. Active years: 2006-2007.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Reinhold Müller. Retrieved from https://idiyas.com/inventor/reinhold-muller

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 6.5

ph-index = 2

Forward Citations = 29(Granted Patents)


Company Filing History:


Years Active: 2006-2007

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Reinhold Müller: Innovator in PARP Inhibitors

Introduction

Reinhold Müller is a notable inventor based in Schifferstadt, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of PARP inhibitors. With a total of 2 patents, his work has the potential to impact drug development and cancer treatment.

Latest Patents

Müller's latest patents include innovative compounds such as substituted benzimidazoles and substituted indoles. These compounds are designed to act as inhibitors of the enzyme poly(ADP-ribose) polymerase, commonly known as PARP. His inventions focus on the preparation and application of these novel derivatives for producing effective drugs.

Career Highlights

Throughout his career, Reinhold Müller has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with BASF Aktiengesellschaft and Abbott GmbH & Co. KG. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Müller has collaborated with several professionals in his field, including Roland Grandel and Wilfried Lubisch. These partnerships have likely enhanced his research and development efforts, leading to successful patent applications.

Conclusion

Reinhold Müller is a distinguished inventor whose work in PARP inhibitors showcases his commitment to advancing pharmaceutical science. His contributions are poised to make a significant impact on drug development and cancer treatment.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…